Treatment of Diabetic Neuropathy with Pentoxifylline: Case Report

Kalmansohn, Robert B.; Kalmansohn, Richard W.; Markham, Charles H.; Schiff, David L.

doi:10.1177/000331978803900407

Cited by 11 publications

(9 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…said in his report that pentoxifylline is likely to increase blood flow to small vessels and improve neuropathy due to reduced blood viscosity and increased flexibility of red blood cells. [18]…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of pentoxifylline on diabetic distal polyneuropathy in type 2 diabetic patients: A randomized trial

et al. 2019

View full text Add to dashboard Cite

Background:Diabetes is one of the most common causes of peripheral neuropathy. There are no known cures for diabetic neuropathy. Pentoxifylline could theoretically be a beneficial treatment for diabetic sensory neuropathy, but there is not enough evidence to prove its effect. The aim of this study was to investigate the effect of pentoxifylline on distal diabetic neuropathy.Materials and Methods:In this randomized double-blinded placebo-controlled trial, 60 patients with diabetic peripheral neuropathy were randomized into two groups. The intervention group received Vitamin B1 (100 mg twice daily) and pentoxifylline (400 mg twice daily) and control group received Vitamin B1 (100 mg twice daily) and placebo (twice daily) for 2 months. Before and after the intervention, the symptoms of distal polyneuropathy were recorded by the Michigan Neuropathy Screening Instrument. ANCOVA, Paired t-test, unpaired t-test, Chi-square, and Fisher's exact test were used to compare changes in symptoms and sign of distal polyneuropathy.Results:The mean age of patients was 57.1 ± 8.02 years. There was no significant difference between the two groups in regard to the baseline variables. Blood pressure, body mass index, and blood glucose did not change significantly during the study. In the pentoxifylline group, the symptoms of peripheral neuropathy were significantly improved, in comparison with placebo group (P = 0.042).Conclusion:This study showed pentoxifylline could be effective in reducing the symptoms of distal diabetic neuropathy.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Most studies have suggested that the effect of pentoxifylline is by reducing the viscosity of the blood and increasing the resiliency of red blood cells and thereby increasing the blood flow of the nerves. [18] Satoh et al . suggested that pentoxifylline can improve diabetic neuropathy by reducing TNF-α and reducing free radicals.…”

Section: Discussionmentioning

confidence: 99%

Effect of pentoxifylline on diabetic distal polyneuropathy in type 2 diabetic patients: A randomized trial

et al. 2019

View full text Add to dashboard Cite

show abstract

“…When Px first became available reports of dramatic improvement in DSP symptoms were reported in both single cases and unrandomized observational studies involving small numbers of subjects [17,18]. Unfortunately, these results have not been repeated in the majority of randomized, placebo-controlled trials [19][20][21].…”

Section: Diabetic Distal Symmetrical Polyneuropathymentioning

confidence: 99%

Are the Protean Effects of Pentoxifylline in the Therapy of Diabetes and Its Complications Still Relevant?

Bell

2021

Diabetes Ther

View full text Add to dashboard Cite

Pentoxifylline (Px) has protean effects that can be utilized in the therapy of diabetes and its complications. There have been well-documented but often inconclusive improvements in peripheral arterial disease, foot ulcers, peripheral neuropathy, nephropathy, retinopathy, ischemic heart disease and cerebrovascular disease. In addition, non-alcoholic steatosis and steatohepatitis, which are closely associated with insulin resistance and type 2 diabetes, have been shown to improve with pentoxifylline. Surprisingly, pentoxifylline modestly improves insulin resistance through improvements in capillary blood flow as well as beta cell function and decreased hepatic glucose production. The therapeutic effects of pentoxifylline are complementary to the effects of drugs such as blockers of the renin-angiotensin-aldosterone system when utilized in the therapy of diabetic nephropathy.

show abstract

“…After completing screening history and physical and laboratory OX-DIABETES CARE, VOLUME 18, NUMBER 3, MARCH 1995 Placebo Before 53.5 ± 5.2 18 16 ± 4 16 46.0 ± 6.2 30 16 ± 6 31 3.5 ± 0.4 18 12 ±5 18 3.8 ± 0.9 20 …”

Section: E T H O D S -mentioning

confidence: 99%

“…This agent has also reportedly improved diabetic microvascular (25)(26), macrovascular (27)(28), and symptomatic diabetic neuropathic syndromes (29)(30)(31) in some patients. Reports of improvement in the vascular function (32)(33), glycemic control (34)(35), and proteinuria (36)(37)(38) have recently been published.…”

mentioning

confidence: 92%